Tag Archives: Therapy

Community-led distribution of HIV self-testing increases uptake of HIV testing and antiretroviral therapy in Malawi

A study from Malawi has found that short-term campaigns of HIV self-testing, whose design and implementation are led by community groups, can rapidly increase the uptake of HIV testing and antiretroviral therapy among underserved populations. Recently published in PLOS Medicine, the study also reported a lower cost for this intervention than for other testing programmes.… Read More »

Injectable HIV therapy would have to cost less than $131 a year to be cost-effective in Africa

A cost-effectiveness analysis has found that injectable, long-lasting antiretroviral therapy (ART) would need to cost no more than $ 131 a year in order to be cost-effective if used for patients who are not fully virally suppressed in lower-income settings in regions like sub-Saharan Africa. The analysis found that injectable cabotegravir/rilpivirine would only reach the… Read More »

FDA Approves Kesimpta (ofatumumab) Targeted B-cell Therapy for Patients with Relapsing Multiple Sclerosis

FDA Approves Kesimpta (ofatumumab) Targeted B-cell Therapy for Patients with Relapsing Multiple Sclerosis Print this page Basel, August 20, 2020 — Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta® (ofatumumab, formerly OMB157) as an injection for subcutaneous use for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically… Read More »

FDA Approves Viltepso (viltolarsen) for the Treatment of Duchenne Muscular Dystrophy in Patients Amenable to Exon 53 Skipping Therapy

FDA Approves Viltepso (viltolarsen) for the Treatment of Duchenne Muscular Dystrophy in Patients Amenable to Exon 53 Skipping Therapy Print this page PARAMUS, N.J., Aug. 12, 2020 /PRNewswire/ — NS Pharma, Inc. announced today that the U.S. Food & Drug Administration (FDA) has approved Viltepso (viltolarsen) injection for patients with Duchenne muscular dystrophy (DMD) who… Read More »

Blood pressure drug improves response to cancer therapy

Scientists at Heidelberg University Hospital and the European Molecular Biology Laboratory (EMBL) have discovered that a drug to lower blood pressure alters the tissue characteristics of secondary tumours, or metastases, from colon cancer. The ‘stiffness’ of these metastases has an effect on the success of cancer therapies. The results are published in Cancer Cell. Heidelberg… Read More »